Who Owns Rapport Therapeutics Stock?
NASDAQ: RAPPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 86.38%
- Held by insiders
- 3.17%
- Institutional holders
- 226
- Institutions 86.4%
- Insiders 3.2%
- Public and other 10.5%
Who owns Rapport Therapeutics stock?
Institutional investors own about 86.4% of Rapport Therapeutics's shares, spread across 226 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 3.17% of RAPP.
The largest institutional holders are FMR, LLC (12.14%), Trv Gp V, LLC (10.59%) and Arch Venture Management, Llc (6.29%). Together, the top 10 institutions control 56.5% of shares outstanding. In their latest filings, 3 of the top 10 institutions increased their RAPP positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of RAPP
| Institution | Shares | % Held | Change |
|---|---|---|---|
| FMR, LLC | 7.20M | 12.14% | +0.3% |
| Trv Gp V, LLC | 6.28M | 10.59% | 0.0% |
| Arch Venture Management, Llc | 3.73M | 6.29% | 0.0% |
| Goldman Sachs Group Inc | 2.97M | 5.02% | +2.2% |
| Blackrock Inc. | 2.88M | 4.86% | +6.7% |
| Capital International Investors | 2.65M | 4.48% | -9.2% |
| Cormorant Asset Management, LP | 2.46M | 4.15% | -7.5% |
| Sofinnova Investments, Inc. | 1.90M | 3.21% | 0.0% |
| Johnson & Johnson | 1.78M | 3.01% | 0.0% |
| Polar Capital Holdings PLC | 1.60M | 2.71% | -0.3% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of RAPP
| Fund | Shares | % Held |
|---|---|---|
| SmallCap World Fund Inc | 3.12M | 5.26% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.32M | 3.92% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 986.73K | 1.66% |
| iShares Trust-iShares Russell 2000 ETF | 793.83K | 1.34% |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 703.00K | 1.19% |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 603.31K | 1.02% |
| T. Rowe Price Health Sciences Fund, Inc. | 571.90K | 0.96% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 335.42K | 0.57% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 332.16K | 0.56% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 328.60K | 0.55% |
Frequently asked questions
Who is the largest shareholder of Rapport Therapeutics?
FMR, LLC is the largest institutional shareholder of RAPP, owning 12.14% of shares outstanding (7.20M shares) as of its latest 13F filing.
What percentage of Rapport Therapeutics is owned by institutions?
Institutions own about 86.4% of RAPP shares and 89.2% of the public float.
How much of Rapport Therapeutics do insiders own?
Insiders, such as officers and directors, own about 3.17% of RAPP shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.